What they found
TL;DR (qwen3.6:35b): This article reviews secondary autoimmune sensorineural hearing loss, emphasizing that early diagnosis is critical to prevent profound hearing loss requiring cochlear implants. It outlines current diagnostic criteria and treatment options ranging from immunosuppression to gene therapy.
Secondary autoimmune sensorineural hearing loss (sASNHL, secondary autoimmune inner ear disease, sAIED) is hearing impairment that might occur in case of systemic or organ-specific autoimmune disorders before or after the main disease manifestation. The onset of sensorineural hearing loss before the specific clinical picture of the underlying disease with a difference of several months and years can lead to serious diagnostic errors. The relevance of the sASNHL issue is due to the risk of developing profound hearing loss that is poorly corrected using traditional methods and may finally require cochlear implantation. All the diagnostic mistakes do happen because of lack of data about sASNHL pathogenesis and clinical features that delay its diagnostics and thus treatment. The significance of sASNHL problem is determined by increase of number of autoimmune pathology in recent decades and their adverse outcomes. The article presents up-to-date information on etiopathogenesis, pathomorphology, clinical features, laboratory, genetic and radiation diagnostic methods, and criteria for the verification of sASNHL. Therapy options using both traditional means of immunosuppression (corticosteroids, cytostatics) and modern biological drugs, as well as progressive and promising semi-surgical methods are described in detail. Gene therapy opportunities are also shown.
How this applies to our program
While the paper focuses on autoimmune mechanisms rather than STRC/DFNB16 genetics, it highlights gene therapy as a promising treatment avenue for severe hearing loss, which is relevant to the broader therapeutic landscape of the program. Additionally, understanding the diagnostic challenges of hearing loss onset helps contextualize the importance of early genetic screening for conditions like DFNB16.
Key numbers
- Several months and years
- Traditional means of immunosuppression (corticosteroids, cytostatics)
- Modern biological drugs
Links
- pubmed_id: https://pubmed.ncbi.nlm.nih.gov/42117417/
- DOI: https://doi.org/10.17116/otorino20269102157
Connections
[source]auto-indexed 2026-05-13 by strc-lit-watch